BRAINBox Solutions, Inc. specializes in developing and manufacturing diagnostic tests for traumatic brain injury (TBI), particularly mild traumatic brain injury. Based in Richmond, Virginia, the company employs a multi-modality approach that integrates blood biomarker panels, neurocognitive testing, and point-of-care instruments to provide objective evidence of injury and predict patient recovery. Its quantitative tests combine injury-related blood protein biomarkers with computerized neurological assessments, enhancing the accuracy of diagnoses and prognoses. Founded in 2002, BRAINBox Solutions aims to lead the industry in TBI assessment and management through innovative solutions.
SonoMotion Inc. develops non-invasive solutions for kidney stone disease. It offers Break Wave, which fragments large kidney stones; and Stone Clear that helps clear the resulting stone fragments within 15 minutes in an office setting and also without general anesthesia or X-ray radiation. SonoMotion Inc. was founded in 2012 and is based in San Mateo, California.
Kanova is a biopharmaceutical firm.
Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.
Unified Information Devices, Inc. specializes in the development and manufacturing of identification solutions for laboratory animals. Founded in 2014 and located in Lake Villa, Illinois, the company offers a range of products, including implantable transponders, microchips, external transponders, readers, multiple tag programmers, and customized software. Their RFID microchip products provide a secure method for identifying animals, vials, and cages. Additionally, Unified Information Devices utilizes advanced software for comprehensive data collection, enabling researchers to efficiently track body weights, mass measurements, blood and tissue samples, and vial locations. This integration of technology enhances the quality and accuracy of data generation in research environments.
CoNextions Medical, Inc. manufactures tendon repair surgical healthcare equipment. It offers CoNextionsTR, a stainless steel and ultra-high molecular weight polyethylene implant that is designed for the surgically address tendon injuries. The company was founded in 2011 and is headquartered in Salt Lake City, Utah.
Testing that is performed near or at the site of patient care with the result leading to possible change in the course of care of the patient. Testing that is performed outside a central laboratory environment, generally nearer to, or at the site of the patient. Also referred to as “near-patient” testing, or “point-of-need testing
Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.
Nano-Micro Technology is a hardware company, which provides uniformly sized nano- and microspheres.
InSeal Medical Ltd. is a company based in Caesarea, Israel, specializing in the development and manufacturing of percutaneous vascular closure devices. The company’s flagship product, the InSeal intravascular closure device, is designed to effectively seal puncture sites resulting from medical procedures that utilize large bore sheaths. This innovative technology employs an internal biodegradable membrane that adheres to the vessel wall, supported by a self-expandable frame. By facilitating the closure of punctures in vessels ranging from 6 to 10 millimeters in diameter, InSeal Medical aims to enhance patient safety and improve recovery outcomes in vascular procedures. The company operates as a subsidiary of E-Pacing Inc.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.
Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.
Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.
Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.
Cardiosolutions, Inc. designs and develops a product for mitral regurgitation problem. The company develops Mitra-Spacer, a reversible implantable device that provides a sealing surface for the leaflets of the mitral valve, thereby reducing or eliminating mitral regurgitation. It serves patients of various ages who suffer from moderate to severe mitral regurgitation, including those who are currently in congestive heart failure. Cardiosolutions, Inc. was founded in 2005 and is based in West Bridgewater, Massachusetts.
Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.
Sciona
Venture Round in 2007
Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.
Spirus Medical is a developer of advanced care medical devices for the gastrointestinal and cardiovascular markets. The company’s product portfolio includes the Endo-Ease Discovery and Dexterity Steerable Introducer.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.
Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.
Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.
Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.
Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.
Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.
Pintex Pharmaceuticals, Inc. is a private pharmaceutical company located in Watertown, Massachusetts, dedicated to the discovery and development of structure-based cancer therapeutics. The company primarily focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a significant role in cancer progression. Founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard, along with Nobel laureate Dr. Walter Gilbert and Dr. Janusz Sowadski, Pintex was established to leverage years of research and patented discoveries from the Salk Institute for Biological Studies and Harvard University. The company's innovative approach aims to develop novel cancer therapeutics and diagnostics rooted in advanced scientific research.
Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.
Verax Biomedical, Incorporated is a medical products company focused on developing rapid tests for detecting bacterial contamination in blood cells and tissues intended for transplantation and cellular therapies. Founded in 1999 and based in Marlborough, Massachusetts, the company addresses a critical need in the field of transfusion medicine, as traditional testing primarily targets viral contaminants, leaving bacterial risks largely unaddressed. Bacteria can proliferate in stored cellular materials, potentially growing from negligible levels at the time of collection to dangerous levels by the time of transfusion or transplantation. Verax Biomedical’s offerings include platelet and red cell Pan Genera Detection tests, designed to identify shared antigens found on various gram-positive and gram-negative bacteria. These tests enable blood banks to effectively detect and mitigate the risks associated with bacterial contamination, thereby enhancing the safety of blood transfusions and cellular therapies.
Pintex Pharmaceuticals, Inc. is a private pharmaceutical company located in Watertown, Massachusetts, dedicated to the discovery and development of structure-based cancer therapeutics. The company primarily focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a significant role in cancer progression. Founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard, along with Nobel laureate Dr. Walter Gilbert and Dr. Janusz Sowadski, Pintex was established to leverage years of research and patented discoveries from the Salk Institute for Biological Studies and Harvard University. The company's innovative approach aims to develop novel cancer therapeutics and diagnostics rooted in advanced scientific research.
Provider of integrated data collection and data management solutions for clinical trials and drug safety